Analysis of Risk Factors for Mucormycosis in COVID-19 Patients Admitted in Tertiary Care Hospital Aurangabad

Introduction: Mucormycosis manifests as various syndromes in human beings, particularly in immunocompromised patients and those with diabetes mellitus. Recently, several cases of mucormycosis in people with COVID19 have been increasingly reported worldwide, especially from India. This prompted us to conduct a study in mucormycosis patients with COVID-19, to know its clinical profile of the COVID-19 patients with mucormycosis and identify of various risk factors in mucormycosis patients with COVID-19 infection.

Materials and Methods: This Cross sectional Retrospective Qualitative Descriptive study was conducted in Department of Medicine, MGM Medical College and Hospital, Aurangabad [Maharashtra]. A total of 100 patients admitted from April 2021 to August 2021 were enrolled as study participants. All COVID-19 patients admitted in MGM who are diagnosed with mucormycosis by microbiologically (KOH mount) or radiologically (CT/MRI) or by histopathology.

Observations and Results: The mean age of patients was 59.72±12.47 years. The male 73 (73.0%) predomianance than female 27(27.0%). 88(88.0%) of patients were having Diabetic Mellitus and 31(31.0%) of patients were having hypertension. All the patients were given Antibiotic & steroids during treatment of COVID-19 at hospitalisation. 15(15.0%) of patients were admitted in ICU during treatment of COVID-19. 76(76.0%) patients were required Oxygen, 03(3.0%) were on NIV/Ventilator and 08 (8.0%) patients were on HFOT during treatment of COVID-19. Overall (97.0%) of patients were recovered.

Conclusion: Diabetes mellitus is identified as the leading underlying comorbidity in cases diagnosed with mucormycosis in post COVID-19 patients. Also use of steroid, duration of use of steroid, and oxygen therapy during the treatment of COVID-19 were risk factors observed in the patients with mucormycosis.